Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04565145 · ClinicalTrials.gov registry record · Phase 2
Biomarker Changes and Anxiolytic Effects-Phase 2
A Phase 2 study, sponsored by University of Florida.
- Completed
- Registry status
- Phase 2
- Development phase
- 39
- Enrollment target
NCT04565145 is a Phase 2 study that has completed, run by University of Florida. The registered enrollment target is 39 participants.
The verdict
NCT04565145, a Phase 2 study, has completed, sponsored by University of Florida.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 39 participants
- Enrollment target
Study Summary
This study will examine the utility of plasma and urinary based biomarkers for the anxiolytic properties of kava. The investigators will conduct a one week, double blind, randomized placebo controlled trial of kava, dosed at three 75 mg capsules per day, vs placebo, in adults with generalized anxiety disorder.
Interventions
- DRUG Placebo
- DRUG Kava Dietary Supplement
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2021-04-05 |
| Est. Completion | 2023-07-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04565145
The ClinicalTrials.gov registry entry for NCT04565145 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Florida, which has 1,106 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04565145 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04565145 about?
NCT04565145 is a clinical study titled "Biomarker Changes and Anxiolytic Effects-Phase 2". This study will examine the utility of plasma and urinary based biomarkers for the anxiolytic properties of kava. The investigators will conduct a one week, double blind, randomized placebo controlled trial of kava, dosed at three 75 mg capsules per day, vs placebo, in adults with generalized anxiet...
What is the current status of trial NCT04565145?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 39 participants. The study started on 2021-04-05. Estimated completion is 2023-07-01.
What interventions are being tested in trial NCT04565145?
The interventions under investigation include: Placebo (DRUG), Kava Dietary Supplement (DRUG).
Who is sponsoring clinical trial NCT04565145?
This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.